Peptris is an AI-powered preclinical drug discovery company focused on oncology, inflammation, and rare diseases. The company has built a suite of proprietary AI models that predict key parameters required for a novel molecule to qualify as a viable drug candidate. These models are integrated into an automated discovery pipeline that systematically filters large, commercially available compound libraries to identify high-quality hits, while also generating de novo molecular designs predicted to be novel, potent, selective, safe, and clinically relevant. By dramatically reducing the number of compounds that require wet-lab testing, Peptris enables a discovery process that is faster, more efficient, and significantly more cost-effective.
